Posted by Michael Wonder on 03 Apr 2025
Novartis receives FDA accelerated approval for Vanrafia (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy
3 April 2025 - Phase 3 data showed Vanrafia achieved proteinuria reduction of 36.1% (P<0.0001) vs. placebo with improvements seen at Week 6 and sustained through Week 36 and favourable safety.
Novartis today announced the US FDA has granted accelerated approval for Vanrafia (atrasentan), a potent and selective endothelin A receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression.
